Advances in Toxoplasma Research and Application: 2012 Edition: ScholarlyBrief

ScholarlyEditions
Free sample

Advances in Toxoplasma Research and Application / 2012 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Toxoplasma in a concise format.

The editors have built Advances in Toxoplasma Research and Application / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Toxoplasma in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Advances in Toxoplasma Research and Application / 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility.

Read more
Collapse
Loading...

Additional Information

Publisher
ScholarlyEditions
Read more
Collapse
Published on
Dec 26, 2012
Read more
Collapse
Pages
101
Read more
Collapse
ISBN
9781481604758
Read more
Collapse
Read more
Collapse
Best For
Read more
Collapse
Language
English
Read more
Collapse
Genres
Medical / Parasitology
Read more
Collapse
Content Protection
This content is DRM protected.
Read more
Collapse

Reading information

Smartphones and Tablets

Install the Google Play Books app for Android and iPad/iPhone. It syncs automatically with your account and allows you to read online or offline wherever you are.

Laptops and Computers

You can read books purchased on Google Play using your computer's web browser.

eReaders and other devices

To read on e-ink devices like the Sony eReader or Barnes & Noble Nook, you'll need to download a file and transfer it to your device. Please follow the detailed Help center instructions to transfer the files to supported eReaders.
The rationale for the design of structural analogues of a normal metabolite is that such compounds may interfere in the utilization or function of the metabolite. A compound which is effective in this respect may be called an antimetabolite. To be successful in chemotherapy of bacterial, viral, or tumor growth, an antimetabolite should adversely affect some vital metabolic reactions in the parasite or parasitic tissue without seriously endangering the host tissue. If a metabolic process of the offending growth is different from that of the host, it is likely that the metabolism or activity of a compound, structurally related to a metabolite involved in that process, will also be different in these cells. Such differences are useful for devising effective drugs with selective actions. Sulfanilamide, a structural analogue of para aminobenzoic acid, interferes with the utilization of this metabolite in the synthesis of folic acid, an essential factor for growth. Bacteria synthesize their own folic acid and are incapable of utilizing exogenously available folic acid. However, the situation is exactly opposite in the animal host. That is, animal tissues cannot synthesize folic acid and are absolutely dependent upon exogenous sources. These differences in metabolism make possible the use of sulfanilamide as a selective inhibitor of growth. Other antibacterial or antiparasitic drugs, such as penicillin (BURCHALL, FERONE and HITCHINGS, 1965) and inhibitors of dihydrofolate reductase (HITCHINGS and BURCHALL, 1965; HITCHINGS, 1964; BURCHALL and HITCHINGS, 1965) have analogous desirable selective toxicity effects.
©2019 GoogleSite Terms of ServicePrivacyDevelopersArtistsAbout Google|Location: United StatesLanguage: English (United States)
By purchasing this item, you are transacting with Google Payments and agreeing to the Google Payments Terms of Service and Privacy Notice.